These findings demonstrated that CAR-NK cells targeting B7-H6 exhibit greater specific killing of fulvestrant-resistant breast cancer cells than regular NK cells do, underscoring the promise of CAR-based cell therapy in overcoming endocrine-resistant breast cancer [65]. This evidence concerns the gene NCR3LG1 and breast carcinoma.